Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2003 1
2009 1
2010 1
2011 2
2013 2
2014 1
2015 2
2016 1
2017 2
2018 1
2019 3
2020 1
2021 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
Tefferi A, Alkhateeb H, Gangat N. Tefferi A, et al. Blood Cancer J. 2023 Jul 18;13(1):108. doi: 10.1038/s41408-023-00878-8. Blood Cancer J. 2023. PMID: 37460550 Free PMC article. Review.
Leukemic transformation in myeloproliferative neoplasms (MPN), also referred to as "blast-phase MPN", is the most feared disease complication, with incidence estimates of 1-4% for essential thrombocythemia, 3-7% for polycythemia vera, and 9-13% for primary myelofibrosis …
Leukemic transformation in myeloproliferative neoplasms (MPN), also referred to as "blast-phase MPN", is the most feared disease complicatio …
Primary myelofibrosis: update on definition, pathogenesis, and treatment.
Abdel-Wahab OI, Levine RL. Abdel-Wahab OI, et al. Annu Rev Med. 2009;60:233-45. doi: 10.1146/annurev.med.60.041707.160528. Annu Rev Med. 2009. PMID: 18947294 Review.
Primary myelofibrosis (PMF) is a clonal stem cell disorder that manifests clinically as anemia, splenomegaly due to extramedullary hematopoiesis, leukoerythroblastosis, and constitutional symptoms, which are the clinical hallmarks of PMF. Within the past three years …
Primary myelofibrosis (PMF) is a clonal stem cell disorder that manifests clinically as anemia, splenomegaly due to extramedul …
Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management.
Casini A, Fontana P, Lecompte TP. Casini A, et al. J Thromb Haemost. 2013 Jul;11(7):1215-27. doi: 10.1111/jth.12265. J Thromb Haemost. 2013. PMID: 23601811 Free article. Review.
The identification of patients at risk who may benefit from antithrombotic therapy remains a challenge, and it is currently based on age and history of thrombotic events. ...The long-term treatment options to prevent thrombosis are, schematically, aspirin alone as prima …
The identification of patients at risk who may benefit from antithrombotic therapy remains a challenge, and it is currently based on …
Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.
Arachchillage DR, Laffan M. Arachchillage DR, et al. Semin Thromb Hemost. 2019 Sep;45(6):604-611. doi: 10.1055/s-0039-1693477. Epub 2019 Aug 5. Semin Thromb Hemost. 2019. PMID: 31382304 Free article. Review.
Chronic myeloproliferative neoplasms (MPN) are characterized by clonal expansion of an abnormal hematopoietic stem/progenitor cell and include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Venous thrombosis, often at unusua …
Chronic myeloproliferative neoplasms (MPN) are characterized by clonal expansion of an abnormal hematopoietic stem/progenitor cell and inclu …
Managing myelofibrosis (MF) that "blasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF.
Scherber RM, Mesa RA. Scherber RM, et al. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):118-126. doi: 10.1182/asheducation-2018.1.118. Hematology Am Soc Hematol Educ Program. 2018. PMID: 30504300 Free PMC article. Review.
Danazol, erythropoietin-stimulating agents, and spleen-directed therapies can be useful in the ruxolitinib-resistant setting. In the ruxolitinib-refractory or -intolerant setting, commercial and novel therapies, either alone or in combination with ruxolitinib, have …
Danazol, erythropoietin-stimulating agents, and spleen-directed therapies can be useful in the ruxolitinib-resistant setting. In the …
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A, Barbui T. Tefferi A, et al. Am J Hematol. 2015 Feb;90(2):162-73. doi: 10.1002/ajh.23895. Am J Hematol. 2015. PMID: 25611051 Free article. Review.
The same molecular markers are also present in prefibrotic myelofibrosis, which needs to be morphologically distinguished from ET. ...Presence of extreme thrombocytosis might be associated with acquired von Willebrand syndrome (AvWS) and, therefore, risk of bleeding. RISK- …
The same molecular markers are also present in prefibrotic myelofibrosis, which needs to be morphologically distinguished from ET. .. …
Pacritinib: a new agent for the management of myelofibrosis?
Beauverd Y, McLornan DP, Harrison CN. Beauverd Y, et al. Expert Opin Pharmacother. 2015;16(15):2381-90. doi: 10.1517/14656566.2015.1088831. Expert Opin Pharmacother. 2015. PMID: 26389774 Review.
INTRODUCTION: Myelofibrosis (MF) is a clonal haematological disease associated with recurrent somatic gene mutations (JAK2V617F, MPL, CALR) and constitutive activation of the Janus kinase (JAK)/Signal Transducer and Activator of Transcription pathway. MF is often ch …
INTRODUCTION: Myelofibrosis (MF) is a clonal haematological disease associated with recurrent somatic gene mutations (JAK2V617 …
A contemporary approach to the diagnosis and management of polycythemia vera.
Tefferi A. Tefferi A. Curr Hematol Rep. 2003 May;2(3):237-41. Curr Hematol Rep. 2003. PMID: 12901345 Review.
The natural history of polycythemia vera (PV) includes an increased lifetime risk of thrombohemorrhagic complications and disease transformation into myelofibrosis with myeloid metaplasia and acute myeloid leukemia. The latter is the primary reason for the shortenin …
The natural history of polycythemia vera (PV) includes an increased lifetime risk of thrombohemorrhagic complications and disease transforma …
Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies.
Finazzi MC, Lussana F, Salmoiraghi S, Spinelli O, Rambaldi A. Finazzi MC, et al. Expert Rev Hematol. 2017 Jul;10(7):627-636. doi: 10.1080/17474086.2017.1331125. Epub 2017 May 25. Expert Rev Hematol. 2017. PMID: 28504024 Review.
Myelofibrosis (MF) is the most aggressive form among Philadelphia negative (Ph-) myeloproliferative neoplasms (MPNs). In the last years, the mutational landscape of MF has expanded remarkably by the identification of additional recurrent mutations, called subclonal …
Myelofibrosis (MF) is the most aggressive form among Philadelphia negative (Ph-) myeloproliferative neoplasms (MPNs). In the last yea …
20 results